论文部分内容阅读
目的:探讨硼替佐米对卵巢癌SKOV-3/DDP细胞增殖和耐药逆转的影响和作用机制。方法:采用MTT法检测不同浓度硼替佐米和顺铂(DDP,cisplatin)对SKOV-3/DDP不同作用时间的细胞生长抑制率,以及硼替佐米和DDP合用和单独应用时的细胞生长抑制率;流式细胞术检测细胞凋亡和细胞周期的变化。结果:硼替佐米能够有效抑制SKOV-3/DDP细胞增殖,硼替佐米与DDP合用组的SKOV-3/DDP细胞抑制率较硼替佐米和DDP单用组均明显增强。单独应用硼替佐米细胞周期阻滞于G2/M期,单独应用DDP细胞周期阻滞于S期,两药联合出现更明显的S期阻滞。结论:硼替佐米与DDP具有协同作用,能够逆转SKOV-3/DDP细胞对DDP的耐药性。
Objective: To investigate the effect and mechanism of bortezomib on proliferation and drug resistance reversal of ovarian cancer SKOV-3 / DDP cells. Methods: MTT assay was used to detect the cell growth inhibition rate of SKOV-3 / DDP treated with different concentrations of bortezomib and cisplatin (DDP), and the cell growth inhibition rate of bortezomib and DDP Flow cytometry was used to detect the changes of apoptosis and cell cycle. RESULTS: Bortezomib could effectively inhibit the proliferation of SKOV-3 / DDP cells. Compared with bortezomib and DDP alone, the SKOV-3 / DDP cells in bortezomib and DDP groups showed significantly higher inhibition rate. Bortezomib alone was blocked in G2 / M phase alone, and cell cycle arrest in S phase alone was performed. S-phase arrest was more obvious in both groups. CONCLUSION: Bortezomib has a synergistic effect with DDP, which can reverse the drug resistance of SKOV-3 / DDP cells to DDP.